Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

38.21 -0.17 (-0.44%)
Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,354,100
Open 38.11
Bid (Size) 37.72 (1)
Ask (Size) 38.48 (2)
Prev. Close 38.38
Today's Range 37.80 - 38.32
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.78%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further... 
Via Benzinga

Performance

YTD
+1.87%
+1.87%
1 Month
-6.53%
-6.53%
3 Month
-9.92%
-9.92%
6 Month
+1.87%
+1.87%
1 Year
+8.27%
+8.27%

More News

Read More
Why Is Moderna Stock Trading Lower On Wednesday?
Via Benzinga
Exposures COVID-19
Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots
Via Investor's Business Daily
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Via Benzinga
UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
Via Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Via FinancialNewsMedia
Topics Death
Exposures Death
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Via Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
Via InvestorPlace
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Via Investor's Business Daily
Exposures COVID-19
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know.
Via InvestorPlace
Topics Lawsuit
Exposures Financial Legal
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
Via Benzinga
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
From GSK plc
Via Business Wire
Is Moderna Stock a Buy Now That It's a 2-Product Company?
Via The Motley Fool
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
From GSK plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.